Comprehensive review of targeted therapy for colorectal cancer

By Yuanhong Xie, Yingxuan Chen, J. Fang. Signal Transduction and Targeted Therapy, 2020

1,433 citations recorded by the source corpus.

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and chemotherapy have long been the first choices for cancer patients. However, the prognosis of CRC has never been satisfying, especially for patients with metastatic lesions. Targeted therapy is a new optional approach that has successfully prolonged overall survival for CRC patients. Following successes with the anti-EGFR (epidermal growth factor receptor) agent cetuximab and the anti-angiogenesis agent bevacizumab, new agents blocking different critical pathways as well as immune checkpoints are emerging at an unprecedented rate. Guidelines worldwide are currently updating the recommended targeted drugs on the basis of the increasing number of high-quality clinical trials. This review provides an overview of existing CRC-targeted agents and their underlying mechanisms, as well as a discussion of their limitations and future trends.

Subfields: Hepatology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/4980bbd78186d8dcd72cea78c224da6b545d763a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

  1. M. A. Hadi
  2. A. Mohiuddin
  3. A. Jairoun
  4. A. John
  5. L. Ming
  6. D. Ooi
  7. Y. Lim
  8. K. Goh

Citations in the corpus